| Patents for A61P 29 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (nsaids) (127,169) |
|---|
| 04/15/2009 | CN101406466A Cinnamic acid transdermal patch and preparation technique thereof |
| 04/15/2009 | CN101406453A Pharmaceutical compositions for oral and topical administration |
| 04/15/2009 | CN101406290A Three-root tea |
| 04/15/2009 | CN100478031C The use of substituted tetracyclic imidazole derivatives as anti-histaminics |
| 04/15/2009 | CN100478029C Immunomodulatory human MHC class II antigen-binding polypeptides |
| 04/15/2009 | CN100478016C Sarcandra solid dispersion and its preparing method |
| 04/15/2009 | CN100478004C Chinese medicinal composistion for treating common cold, its preparation method and quality control method |
| 04/15/2009 | CN100477997C Hydrophobic formulation containing total notoginseng glycosides and phospholipid and preparation method thereof |
| 04/15/2009 | CN100477994C Meloxicam containing skin topical paste formulation |
| 04/15/2009 | CN100477992C Substituted piperazine and piperidine calcium channel blockers |
| 04/15/2009 | CN100477990C Tanshinoue dropping pills and preparing method |
| 04/15/2009 | CN100477989C Ketoprofen cataplasm and its preparing method |
| 04/14/2009 | US7517996 methyl 3-(4-{4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-isoxazolyl}-benzylsulfanyl)propionate; compounds inhibit the physiological activity of lysophosphatidic acid (LPA); treatment of fibrosis of organs (liver, kidney, lung, and the like), hepatic disease |
| 04/14/2009 | US7517989 Piperidine derivatives useful as modulators of chemokine receptor activity |
| 04/14/2009 | US7517987 Interleukin converting enzyme inhibitors such as 5-Fluoro-4-oxo-3-(2-(6-oxo-6H-pyrimidin-1-yl)-butyrylamino)-pentanoic acid, administered as modulators of cell apoptosis and inflammation |
| 04/14/2009 | US7517909 Using 3-amino-5-methyl-octanoic acid for therapy of psychiatric, pain and other disorders |
| 04/14/2009 | US7517892 Ligands for monoamine receptors and transporters, and methods of use thereof |
| 04/14/2009 | US7517879 Pyrrolidine derivatives as factor Xa inhibitors |
| 04/14/2009 | US7517875 Piperidine derivatives having CCR3 antagonism |
| 04/14/2009 | US7517858 Prodrugs of pharmaceuticals with improved bioavailability |
| 04/14/2009 | US7517661 Methods of screening for ligands for FPRL2 |
| 04/14/2009 | US7517529 Using gene-regulatory peptide |
| 04/14/2009 | CA2417050C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
| 04/14/2009 | CA2371789C Novel guanidine derivatives as inhibitors of cell adhesion |
| 04/14/2009 | CA2359440C Phenylphenanthridines with pde-iv inhibiting activity |
| 04/14/2009 | CA2240256C Vascular irrigation solution and method for inhibition of pain, inflammation, spasm and restenosis |
| 04/14/2009 | CA2204493C Application of superoxide dismutase in liposomes |
| 04/09/2009 | WO2009046220A2 Lipopeptides for delivery of nucleic acids |
| 04/09/2009 | WO2009044930A1 Pharmaceutical composition for inhibiting the accumulation of amyloid-β protein |
| 04/09/2009 | WO2009044899A1 Nucleic acid capable of regulating the proliferation of cell |
| 04/09/2009 | WO2009044895A1 Composition inhibiting the expression of target gene |
| 04/09/2009 | WO2009044788A1 Benzoxazinone derivative |
| 04/09/2009 | WO2009044311A1 Thiophene-2-carboxamide derivatives as modulators of ccr9 receptor |
| 04/09/2009 | WO2009044006A2 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic acid the pharmaceutically-acceptable esters and salts and solvates thereof for use as medicament |
| 04/09/2009 | WO2009043836A1 A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases. |
| 04/09/2009 | WO2009043747A2 N-heterocyclic biaryl carboxamides as ccr receptor antagonists |
| 04/09/2009 | WO2009043582A1 Nicotinamide n-oxide derivatives as vanilloid-1 receptor modulators |
| 04/09/2009 | WO2009043525A2 Use of the combination of gluten exorphin c and cd36 as a therapeutic agent |
| 04/09/2009 | WO2009043495A1 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain |
| 04/09/2009 | WO2009043463A2 Use of gluten exorphin c : as a therapeutic agent |
| 04/09/2009 | WO2009043453A2 Use of a peptide as a therapeutic agent |
| 04/09/2009 | WO2009043171A1 Method of regulating the th17 pathway and its associated metabolic impact |
| 04/09/2009 | WO2009043116A1 Methods and compositions for the treatment of phosphatase- related disorders |
| 04/09/2009 | WO2009013171A3 Heterocyclic antiviral compounds |
| 04/09/2009 | WO2008156645A3 Pharmaceutical compositions and uses |
| 04/09/2009 | WO2008149163A3 Potassium ion channel modulators and uses thereof |
| 04/09/2009 | WO2008050168A8 New sulfonamide derivatives as bradykinin antagonists |
| 04/09/2009 | WO2002026020A9 Tricyclic antidepressants and their analogues as long-acting local anesthetics and analgesics |
| 04/09/2009 | US20090093617 Crystals of whole antibodies and fragments thereof and methods for making and using them |
| 04/09/2009 | US20090093508 Therapeutic or prophylactic agent for allergic dermatitis |
| 04/09/2009 | US20090093485 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases |
| 04/09/2009 | US20090093469 Phenylaminopropanol Derivatives and Methods of Their Use |
| 04/09/2009 | US20090093462 3-Arylamino pyridine derivatives |
| 04/09/2009 | US20090093454 Chemical Compounds |
| 04/09/2009 | US20090093442 Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome |
| 04/09/2009 | US20090093433 SENSE mRNA THERAPY |
| 04/09/2009 | US20090093393 Methods For Selective Targeting |
| 04/09/2009 | US20090092613 Novel TNF receptor death domain ligand proteins and inhibitors of ligand binding |
| 04/09/2009 | US20090092611 Antibodies that bind both bcma and taci |
| 04/09/2009 | US20090092605 Compositions and methods for the treatment of immune related diseases |
| 04/09/2009 | US20090092604 Method for the Treatment of Multiple Sclerosis by Inhibiting IL-17 Activity |
| 04/09/2009 | US20090092545 Antibodies that bind both bcma and taci |
| 04/09/2009 | DE4021517B4 Formulierungen mit verlangsamter Freisetzung wasserlöslicher Peptide Formulations with delayed release of water-soluble peptides |
| 04/09/2009 | DE102007046202A1 Medium for preventing or relieving pain, muscular strain particularly in muscle, for improvement of immune condition, wound healing or for reduction or recovery of arteriosclerosis, has mixture of tocotrienols and gamma linolenic acid |
| 04/09/2009 | DE102007046086A1 Pflanzenextrakt aus THC-armen Cannabis zur Behandlung von Erkrankungen Plant extract of low-THC cannabis in treating diseases |
| 04/09/2009 | CA2734139A1 Antibody therapy for use in the digestive tract |
| 04/09/2009 | CA2706241A1 Use of sulfonyl-substituted 2-sulfonylaminobenzoic acid n-phenylamides in the treatment of pain |
| 04/09/2009 | CA2701768A1 Thiophene-2-carboxamide derivatives as modulators of ccr9 receptor |
| 04/09/2009 | CA2701618A1 Pharmaceutical composition for inhibiting amyloid-beta protein accumulation |
| 04/09/2009 | CA2701494A1 Method of regulating the th17 pathway and its associated metabolic impact |
| 04/09/2009 | CA2701406A1 Benzoxazinone derivative |
| 04/09/2009 | CA2701368A1 A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases. |
| 04/09/2009 | CA2701274A1 Lipopeptides for delivery of nucleic acids |
| 04/09/2009 | CA2700691A1 New biaryl derivatives |
| 04/09/2009 | CA2699105A1 Use of a peptide as a therapeutic agent |
| 04/08/2009 | EP2045251A1 Compound that can inhibit ubc13-uev interactions, pharmaceutical compositions and therapeutic uses |
| 04/08/2009 | EP2045250A1 Ring-substituted phenyl pyrrole aminoguanidine derivatives |
| 04/08/2009 | EP2045244A1 Novel crystal of substituted phenylalkanoic acid and production process |
| 04/08/2009 | EP2045243A1 Tetrahydro isoquinoline derivatives, preparation methods and medicinal uses thereof |
| 04/08/2009 | EP2044957A1 Treatment agent for inflammatory bowel disease |
| 04/08/2009 | EP2044955A2 Methods for detecting and inhibiting angiogenesis |
| 04/08/2009 | EP2044935A1 A composition containing non-psychotropic cannabinoids for the treatment of inflammatory diseases |
| 04/08/2009 | EP2044931A2 Pharmaceutical compositions based on porous zeolites as release means of pharmacologically active molecules and relative use |
| 04/08/2009 | EP2044086A2 Thiazolopyrimidine modulators of trpv1 |
| 04/08/2009 | EP2044062A1 Indole compounds |
| 04/08/2009 | EP2044056A1 Pyrimidine derivatives as alk-5 inhibitors |
| 04/08/2009 | EP2044027A2 Fused bicyclic compounds interacting with the histamine h4 receptor |
| 04/08/2009 | EP2043655A2 Purine and deazapurine derivatives as pharmaceutical compounds |
| 04/08/2009 | EP2043651A2 Methods of using igf1r and abl kinase modulators |
| 04/08/2009 | EP2043644A1 Nf- b inhibitor |
| 04/08/2009 | EP2043632A2 New indications for direct thrombin inhibitors |
| 04/08/2009 | EP1682496B1 Analgesic compounds, their synthesis and pharmaceutical compositions containing them |
| 04/08/2009 | EP1594499B1 Dosage forms containing a proton pump inhibitor, a nsaid, and a buffer |
| 04/08/2009 | EP1565475B1 Diazinopyrimidines and their use as protein kinase inhibitors |
| 04/08/2009 | EP1545710B1 Use of n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide in the treatment of cancer |
| 04/08/2009 | EP1448566B3 Chemokine receptor antagonists and methods of use thereof |
| 04/08/2009 | EP1442026B1 Triazole derivatives as cyclooxygenase (cox) inhibitors |
| 04/08/2009 | EP1415986B1 Spiro isobenzofuranes as neuropeptide y receptor antagonists |
| 04/08/2009 | EP1309355B9 Peptide and peptide mimetic conjugates with integrin-inhibitor properties |
| 04/08/2009 | EP1212299B1 Substituted piperidine compounds useful as modulators of chemokine receptor activity |